Company Profile

Pandion Therapeutics, Inc., formerly Pandion Therapeutics Holdco LLC, is a clinical-stage biopharmaceutical company. The Company is focused on developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases. It is developing its Therapeutic Autoimmune reguLatOry protein (TALON) drug design and discovery platform. Its lead product candidate, PT101, a combination of its interleukin-2 (IL-2), mutein effector module with a protein backbone, is designed to selectively expand regulatory Treg cells, without activating proinflammatory cells, such as conventional T cells and natural killer (NK cells).

Employees

Sector

Biotechnology & Medical Research

More about the company

02/04/21	Pandion Therapeutics, Inc.(NasdaqGM:PAND) dropped from NASDAQ Composite Index	CI
01/04/21	Merck : Completes Pandion Therapeutics Acquisition	MT
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from S&P TMI Index	CI
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from S&P Global BMI Index	CI
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from Russell 2000 Index	CI
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from Russell 3000 Index	CI
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from Russell 2500 Index	CI
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from Russell 2000 Growth Index	CI
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from Russell 2000 Value Index	CI
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from Russell Small Cap Completeness Index	CI
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from Russell Small Cap Comp Value Index	CI
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from Russell Small Cap Comp Growth Index	CI
01/04/21	Pandion Therapeutics, Inc.(NasdaqGS:PAND) dropped from Russell 2500 Value Index	CI

27/02/21	Pandion Therapeutics : Morgan Stanley Downgrades Pandion Therapeutics to Equal Weight From Overweight, Adjusts PT to $60 From $25	MT
26/02/21	Pandion Therapeutics : SVB Leerink Downgrades Pandion Therapeutics to Market Perform From Outperform; Price Target is $60	MT

01/04/21	PANDION THERAPEUTICS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
13/03/21	PANDION THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ
02/03/21	PANDION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pandion Therapeutics, Inc. - PAND	BU
25/02/21	PANDION THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
22/02/21	Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting	GL

01/04/21	Merck : a finalisé l'acquisition de Pandion Therapeutics
25/02/21	Pandion Therapeutics : Merck annonce le rachat de Pandion Therapeutics pour 1,85 milliard de dollars
25/02/21	Pandion Therapeutics : Merck annonce le rachat de Pandion Therapeutics pour $1,85 md
25/02/21	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
25/02/21	Merck : US-Pharmariese Merck kauft Pandion Therapeutics für 1,85 Mrd USD

Manager	Title	Age	Since
Gregg Beloff DFI	Director of Finance/CFO	58	-
Nathan Higginson-Scott CTO	Chief Tech/Sci/R&D Officer	-	01/08/2020
Edward Freedman COO	Chief Operating Officer	57	-

Pandion Therapeutics, Inc. Stock

Stocks

PAND

US6983401067

Biotechnology & Medical Research

Latest news : Pandion Therapeutics, Inc.

Analysts' recommendations : Pandion Therapeutics, Inc.

Press Releases : Pandion Therapeutics, Inc.

News in other languages : Pandion Therapeutics, Inc.

Quotes and Performance

Managers and Directors : Pandion Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/4/21	Nancy Stagliano	Tender	Director	91,738	0.3108%
1/4/21	Polaris Growth Management LLC	Tender	Company	3,201,422	10.8465%
1/4/21	Vikas Goyal	Tender	Executive/Senior Manager	189,780	0.6430%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PANDION THERAPEUTICS, INC.	+0.22%	+0.13%	-	-	1.7B
WUXI APPTEC CO., LTD.	-0.25%	-4.10%	+38.38%	+92.61%	68.21B
ARGENX SE	+1.21%	+0.80%	+46.29%	+85.32%	64.25B
INSMED INCORPORATED	-0.25%	-1.92%	-10.72%	+436.70%	26.54B
BIONTECH SE	+0.33%	-10.61%	+1.95%	-16.27%	25.61B
GENMAB A/S	+1.18%	-2.23%	+30.87%	-19.04%	19.88B
PHARMAESSENTIA CORPORATION	-6.09%	-12.08%	+226.11%	+375.00%	17.13B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.33%	-5.63%	-1.48%	+532.58%	14.93B
EXELIXIS, INC.	+4.12%	+0.30%	+52.03%	+150.18%	14.1B
MADRIGAL PHARMACEUTICALS, INC.	-0.24%	+5.18%	+23.04%	+190.97%	12.45B
Average	+0.05%	-3.92%	+45.16%	+203.12%	29.23B
Weighted average by Cap.	+0.16%	-3.22%	+41.21%	+157.60%